髂静脉支架置入的临床结局:单中心回顾性延长随访研究
单中心回顾性研究纳入2016年4月至2023年6月连续105例髂静脉支架置入患者,平均随访54个月,分为非血栓性髂静脉病变、血栓后综合征和急性深静脉血栓三组。5年一期通畅率分别为97.4%、87.0%和100%,辅助一期及二期通畅率均高于一期通畅率,临床严重程度评分和CEAP分级末次随访显著改善,4例需再干预,无支架断裂或移位。
要点
- 髂静脉支架置入在三种病因中均显示持续通畅和临床评分改善。
- 5年一期通畅率非血栓性病变97.4%、血栓后综合征87.0%、急性DVT 100%。
- 再干预率低,无支架断裂或移位,支持延长随访下的安全性。
核心结论
- 髂静脉支架置入在不同病因的髂股静脉阻塞患者中延长随访期间与持续通畅和临床评分降低相关。
研究设计与样本
- 回顾性单中心研究纳入2016年4月至2023年6月连续105例接受髂静脉支架置入的患者。
- 患者分为非血栓性髂静脉病变44例、血栓后综合征31例和急性深静脉血栓30例,平均随访54个月。
主要发现
- 5年一期通畅率非血栓性髂静脉病变组97.4%、血栓后综合征组87.0%、急性深静脉血栓组100%。
- 辅助一期和二期通畅率在所有组中均超过一期通畅率。
- 临床严重程度评分和CEAP临床分级在末次随访时显著改善。
- 4例患者需要再干预,未观察到支架断裂或移位。
临床怎么用
- 对于非血栓性髂静脉病变、血栓后综合征和急性深静脉血栓所致的症状性髂股静脉阻塞,髂静脉支架置入可作为维持通畅和改善临床评分的治疗选择。
- 延长随访中需监测再干预,但支架断裂或移位风险低。
局限性
- 本研究为单中心回顾性设计,证据等级受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Iliac vein stenting is used for the treatment of symptomatic iliofemoral venous obstruction caused by nonthrombotic iliac vein lesions, postthrombotic syndrome, and acute deep vein thrombosis. However, evidence regarding mid- to long-term clinical outcomes remains sparse. METHODS: This retrospective single-center study included consecutive patients who underwent iliac vein stenting between April 2016 and June 2023. Patients were categorized into nonthrombotic iliac vein lesion, postthrombotic syndrome, and acute deep vein thrombosis groups. Primary, assisted primary, and secondary patency were evaluated using Kaplan-Meier analysis. Clinical outcomes were assessed using the Clinical-Etiological-Anatomical-Pathophysiological (CEAP) clinical class, Venous Clinical Severity Score, and Villalta score. Adverse events, reinterventions, and device-related outcomes were recorded during follow-up. RESULTS: A total of 105 patients were included, with a mean follow-up of 54 months. The cohort consisted of 44 patients with nonthrombotic iliac vein lesions, 31 with postthrombotic syndrome, and 30 with acute deep vein thrombosis. Technical success was achieved in all procedures. At 5 years, primary patency was 97.4% in the nonthrombotic iliac vein lesion group, 87.0% in the postthrombotic syndrome group, and 100% in the acute deep vein thrombosis group. Assisted primary and secondary patency rates exceeded primary patency across all groups. Clinical severity scores and CEAP classes significantly improved by the final follow-up. Reintervention was required in 4 patients. No stent fracture or migration was observed. CONCLUSION: Iliac vein stenting was associated with sustained patency and clinical score reduction during extended follow-up in patients with different etiologies of iliofemoral venous obstruction.
引用
- Cui HJ, Li ML, Zhao L, et al. Clinical Outcomes of Iliac Vein Stenting: A Single-Center Retrospective Study with Extended Follow-up. Ann Vasc Surg. 2026. PMID: 41956152. doi:10.1016/j.avsg.2026.03.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。